Meyer 2011.

Trial name or title	"Effect of low molecular weight heparin on survival of stage I, II or IIIA non small cell lung cancer. A multicenter, open, randomised controlled trial"
Methods	Phase III, prospective, multicentric, randomised, open trial in parallel groups with a blind adjudication of all endpoint criteria
Participants	Patients with completely resected non‐small cell lung cancer of stage I, II, or IIIA T3N1 confirmed by histology. Patients who had preoperative chemotherapy, those who are selected for adjuvant chemotherapy and those who are not candidates for adjuvant chemotherapy (because they have a contraindication to chemotherapy or they have a stage I cancer) are eligible for the study
Interventions	Tinzaparin sodium 100 UI/kg od for 12 weeks along with usual postoperative care including chemotherapy Control: usual postoperative care including chemotherapy
Outcomes	Primary endpoint: overall 3‐year mortality Secondary outcomes: major bleeding time, symptomatic VTE, cancer‐related mortality, disease‐free survival
Starting date	June 2007
Contact information	Guy Meyer guy.meyer@egp.aphp.fr
Notes	ClinicalTrials.gov Identifier: NCT00475098